The US government has entered an agreement with life sciences company Cytiva, to expand the manufacturing of products needed to make COVID-19 vaccines, the U.S. Department of Health and Human Services (HHS) said on Tuesday.
Under the deal, Cytiva will receive about $31 million to scale up manufacturing of vaccine-related products, including cell cultures and hardware such as bioreactors used for the culturing of cells and antibodies.
The grant will help the company up the manufacturing capabilities of its Massachusetts and Utah facilities.
The US government has till date agreed to pay more than $1.1 billion to purchase needles, syringes, vials and supply kits, as well as expand manufacturing capacity for COVID-19 vaccines and therapeutics in the US, the HHS said.
